MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-09-2022
Clovis Oncology ROA Ratio 2011-2026 | CLVS
Annual ROA Ratio Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -55.94 | -60.97 | -59.8 | -42.62 | -47.11 | -95.77 | -49.46 | -20.35 | -13.01 | -50.68 | -38.74 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.01 | -95.77 | -48.59 |
Quarterly ROA Ratio Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47.64 | -61.25 | -58.37 | -51.83 | -50.58 | -53.3 | -53.02 | -56.64 | -60.97 | -59.49 | -60.55 | -63.3 | -59.8 | -56.43 | -52.79 | -46.52 | -42.62 | -38.18 | -36.02 | -48.16 | -47.11 | -59.46 | -69.23 | -80.84 | -95.77 | -93.13 | -88.93 | -63.49 | -49.46 | -39.77 | -30.98 | -25.38 | -20.43 | -17.87 | -15.95 | -14.51 | -13.01 | -22.94 | -32.33 | -40.07 | -50.68 | -46.64 | -43.78 | -45.95 | -38.74 | -9.64 | -12.9 | -5.81 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.81 | -95.77 | -46.51 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.83 | 2.56 % | $ 9.21 B |  Australia |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 327.37 | -1.81 % | $ 42.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.74 | 0.21 % | $ 767 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.48 | 2.39 % | $ 350 M | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 8.22 | 10.78 % | $ 81.3 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.55 | -0.6 % | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 100.72 | 1.25 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.1 | -2.21 % | $ 5.1 M | Israel |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.42 | -8.71 % | $ 365 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.39 | -6.65 % | $ 153 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.18 | -1.3 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.21 | -1.53 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.58 | -1.27 % | $ 6.83 B |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.52 | 1.68 % | $ 405 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-95.49 | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 33.67 | -0.61 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |